Division of Immunology, Children's Hospital and Department of Pediatrics, Harvard Medical School, Boston, MA, USA.
Clin Immunol. 2013 Feb;146(2):84-9. doi: 10.1016/j.clim.2012.11.007. Epub 2012 Dec 7.
X-linked lymphoproliferative (XLP) disease is a primary immunodeficiency syndrome associated with the inability to control Epstein-Barr virus (EBV), lymphoma, and hypogammaglobulinemia. XLP is caused by mutations in the SH2D1A gene, which encodes the SLAM-associated protein (SAP), or in the BIRC4 gene, which encodes the X-linked inhibitor of apoptosis protein (XIAP). Here we report a patient with recurrent respiratory tract infections and early onset agammaglobulinemia who carried a unique disease-causing intronic loss-of-function mutation in SH2D1A. The intronic mutation affected SH2D1A gene transcription but not mRNA splicing, and led to markedly reduced level of SAP protein. Despite undetectable serum immunoglobulins, the patient's B cells replicated and differentiated into antibody producing cells normally in vitro.
X 连锁淋巴组织增生性疾病(XLP)是一种与无法控制 EBV、淋巴瘤和低丙种球蛋白血症相关的原发性免疫缺陷综合征。XLP 是由 SH2D1A 基因的突变引起的,该基因编码 SLAM 相关蛋白(SAP),或由 BIRC4 基因的突变引起的,该基因编码凋亡抑制蛋白(XIAP)。在这里,我们报告了一名患有复发性呼吸道感染和早期发病的无丙种球蛋白血症的患者,他携带了 SH2D1A 基因中的一种独特的致病内含子缺失性功能突变。该内含子突变影响 SH2D1A 基因转录,但不影响 mRNA 剪接,导致 SAP 蛋白水平显著降低。尽管血清免疫球蛋白无法检测到,但患者的 B 细胞在体外仍能正常复制和分化为产生抗体的细胞。